Cargando…

High-flow nasal cannula versus noninvasive ventilation in patients with COVID-19: a systematic review and meta-analysis

BACKGROUND: During the novel coronavirus disease 2019 (COVID-19) pandemic raging around the world, the effectiveness of respiratory support treatment has dominated people’s field of vision. This study aimed to compare the effectiveness and value of high-flow nasal cannula (HFNC) with noninvasive ven...

Descripción completa

Detalles Bibliográficos
Autores principales: He, Yuewen, Liu, Na, Zhuang, Xuhui, Wang, Xia, Ma, Wuhua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8972939/
https://www.ncbi.nlm.nih.gov/pubmed/35318888
http://dx.doi.org/10.1177/17534666221087847
_version_ 1784679956064763904
author He, Yuewen
Liu, Na
Zhuang, Xuhui
Wang, Xia
Ma, Wuhua
author_facet He, Yuewen
Liu, Na
Zhuang, Xuhui
Wang, Xia
Ma, Wuhua
author_sort He, Yuewen
collection PubMed
description BACKGROUND: During the novel coronavirus disease 2019 (COVID-19) pandemic raging around the world, the effectiveness of respiratory support treatment has dominated people’s field of vision. This study aimed to compare the effectiveness and value of high-flow nasal cannula (HFNC) with noninvasive ventilation (NIV) for COVID-19 patients. METHODS: A comprehensive systematic review via PubMed, Web of Science, Cochrane, Scopus, WHO database, China Biology Medicine Disc (SINOMED), and China National Knowledge Infrastructure (CNKI) databases was conducted, followed by meta-analysis. RevMan 5.4 was used to analyze the results and risk of bias. The primary outcome is the number of deaths at day 28. The secondary outcomes are the occurrence of invasive mechanical ventilation (IMV), the number of deaths (no time-limited), length of intensive care unit (ICU) and hospital stay, ventilator-free days, and oxygenation index [partial pressure of arterial oxygen (PaO(2))/fraction of inhaled oxygen (FiO(2))] at 24 h. RESULTS: In total, nine studies [one randomized controlled trial (RCT), seven retrospective studies, and one prospective study] totaling 1582 patients were enrolled in the meta-analysis. The results showed that the incidence of IMV, number of deaths (no time-limited), and length of ICU stay were not statistically significant in the HFNC group compared with the NIV group (ps = 0.71, 0.31, and 0.33, respectively). Whereas the HFNC group performed significant advantages in terms of the number of deaths at day 28, length of hospital stay and oxygenation index (p < 0.05). Only in the ventilator-free days did NIV show advantages over the HFNC group (p < 0.0001). CONCLUSION: For COVID-19 patients, the use of HFNC therapy is associated with the reduction of the number of deaths at day 28 and length of hospital stay, and can significantly improve oxygenation index (PaO(2)/FiO(2)) at 24 h. However, there was no favorable between the HFNC and NIV groups in the occurrence of IMV. NIV group was superior only in terms of ventilator-free days.
format Online
Article
Text
id pubmed-8972939
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-89729392022-04-02 High-flow nasal cannula versus noninvasive ventilation in patients with COVID-19: a systematic review and meta-analysis He, Yuewen Liu, Na Zhuang, Xuhui Wang, Xia Ma, Wuhua Ther Adv Respir Dis Meta-Analysis BACKGROUND: During the novel coronavirus disease 2019 (COVID-19) pandemic raging around the world, the effectiveness of respiratory support treatment has dominated people’s field of vision. This study aimed to compare the effectiveness and value of high-flow nasal cannula (HFNC) with noninvasive ventilation (NIV) for COVID-19 patients. METHODS: A comprehensive systematic review via PubMed, Web of Science, Cochrane, Scopus, WHO database, China Biology Medicine Disc (SINOMED), and China National Knowledge Infrastructure (CNKI) databases was conducted, followed by meta-analysis. RevMan 5.4 was used to analyze the results and risk of bias. The primary outcome is the number of deaths at day 28. The secondary outcomes are the occurrence of invasive mechanical ventilation (IMV), the number of deaths (no time-limited), length of intensive care unit (ICU) and hospital stay, ventilator-free days, and oxygenation index [partial pressure of arterial oxygen (PaO(2))/fraction of inhaled oxygen (FiO(2))] at 24 h. RESULTS: In total, nine studies [one randomized controlled trial (RCT), seven retrospective studies, and one prospective study] totaling 1582 patients were enrolled in the meta-analysis. The results showed that the incidence of IMV, number of deaths (no time-limited), and length of ICU stay were not statistically significant in the HFNC group compared with the NIV group (ps = 0.71, 0.31, and 0.33, respectively). Whereas the HFNC group performed significant advantages in terms of the number of deaths at day 28, length of hospital stay and oxygenation index (p < 0.05). Only in the ventilator-free days did NIV show advantages over the HFNC group (p < 0.0001). CONCLUSION: For COVID-19 patients, the use of HFNC therapy is associated with the reduction of the number of deaths at day 28 and length of hospital stay, and can significantly improve oxygenation index (PaO(2)/FiO(2)) at 24 h. However, there was no favorable between the HFNC and NIV groups in the occurrence of IMV. NIV group was superior only in terms of ventilator-free days. SAGE Publications 2022-03-23 /pmc/articles/PMC8972939/ /pubmed/35318888 http://dx.doi.org/10.1177/17534666221087847 Text en © The Author(s), 2022 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Meta-Analysis
He, Yuewen
Liu, Na
Zhuang, Xuhui
Wang, Xia
Ma, Wuhua
High-flow nasal cannula versus noninvasive ventilation in patients with COVID-19: a systematic review and meta-analysis
title High-flow nasal cannula versus noninvasive ventilation in patients with COVID-19: a systematic review and meta-analysis
title_full High-flow nasal cannula versus noninvasive ventilation in patients with COVID-19: a systematic review and meta-analysis
title_fullStr High-flow nasal cannula versus noninvasive ventilation in patients with COVID-19: a systematic review and meta-analysis
title_full_unstemmed High-flow nasal cannula versus noninvasive ventilation in patients with COVID-19: a systematic review and meta-analysis
title_short High-flow nasal cannula versus noninvasive ventilation in patients with COVID-19: a systematic review and meta-analysis
title_sort high-flow nasal cannula versus noninvasive ventilation in patients with covid-19: a systematic review and meta-analysis
topic Meta-Analysis
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8972939/
https://www.ncbi.nlm.nih.gov/pubmed/35318888
http://dx.doi.org/10.1177/17534666221087847
work_keys_str_mv AT heyuewen highflownasalcannulaversusnoninvasiveventilationinpatientswithcovid19asystematicreviewandmetaanalysis
AT liuna highflownasalcannulaversusnoninvasiveventilationinpatientswithcovid19asystematicreviewandmetaanalysis
AT zhuangxuhui highflownasalcannulaversusnoninvasiveventilationinpatientswithcovid19asystematicreviewandmetaanalysis
AT wangxia highflownasalcannulaversusnoninvasiveventilationinpatientswithcovid19asystematicreviewandmetaanalysis
AT mawuhua highflownasalcannulaversusnoninvasiveventilationinpatientswithcovid19asystematicreviewandmetaanalysis